BioSpace News Archive

EMPA-KIDNEY phase III clinical trial met its primary endpoint by demonstrating a significant kidney and cardiovascular benefit for adults living with chronic kidney disease (CKD).

Aptabio will present Isuzinaxib Phase 2 clinical trial[1] results at the American Society of Nephrology (ASN)'s Kidney Week 2022 in Orlando, FL.

Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced long-term follow-up data from the OPTIC study treating wet age-related macular degeneration (wet AMD) during The Retina Society Annual Meeting in Pasadena, California.

AMPEL BioSolutions today announced a genetic precision medicine test for lupus patients that could save lives by predicting heart disease before it happens and providing decision support for prophylactic therapies.

NKGen Biotech, Inc. today announced a collaboration with the Parkinson’s Foundation that will focus on ways to help accelerate NKGen’s clinical program using its novel autologous NK cell therapy (SNK01) for the treatment of advanced Parkinson’s disease (PD) through its network of clinical partners and donors.

Centene Corporation announced it will present at the Credit Suisse 31st Annual Healthcare Conference, to be held Monday, November 7-Friday, November 11, 2022, at the Terreana Resort in California.